Enabling the global cannabis economy

BOL Pharma is the only company in Israel that is fully accredited under the CMPR throughout the main elements of the value chain. Only IMC-GMP certified companies are able to distribute medical cannabis products domestically to pharmacies and will be able to export internationally. Our first targeting export markets are in the EU as well as Canada and Australia.

Phase IIa clinical trials

Square feet of fully-operational greenhouses

Square feet state of the art IMC-GMP certified manufacturing facility in Revadim, Israel

BOL Pharma has a wide range of expertise in the development and production of high quality, botanical cannabinoid APIs using technology and unique processes.

BOL ADVANTAGES

$

Low-cost structure production capabilities due to favorable climate conditions, regulation, low energy footprint and labor cost.

$

Producing a range of 99% pure cannabinoids: THC, CBD as well as CBN, CBG and CBC to supply commercial, clinical, and research entities.

$

Pipeline of cannabinoid based pharmaceutical products under development across a range of Indications; comprehensive cannabinoid clinical trial portfolio comprising 34 Phase IIa trials.

$

Exclusive licences to incorporate patented drug delivery technologies in our products, including advanced formulations that enhance absorption and improve dosing and shelf stability.

$

PK studies in progress to launch new drug delivery platforms: Sublingual tablets, metered dose inhalers and gel capsules.

$

Trusted IMC GMP certified supplier of APIs to leading pharmaceutical companies, universities and research partnerships and proprietary production procedures for several isolated cannabinoids.